Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
19.45
-0.05 (-0.26%)
At close: Dec 20, 2024, 4:00 PM
19.32
-0.13 (-0.67%)
After-hours: Dec 20, 2024, 4:24 PM EST
Arrowhead Pharmaceuticals Employees
Arrowhead Pharmaceuticals had 609 employees as of September 30, 2024. The number of employees increased by 84 or 16.00% compared to the previous year.
Employees
609
Change (1Y)
84
Growth (1Y)
16.00%
Revenue / Employee
$5,831
Profits / Employee
-$984,389
Market Cap
2.42B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Select Medical Holdings | 54,600 |
| Surgery Partners | 13,500 |
| Concentra Group Holdings Parent | 9,020 |
| Amneal Pharmaceuticals | 7,700 |
| HUTCHMED (China) | 1,988 |
| Privia Health Group | 1,102 |
| Kymera Therapeutics | 187 |
| Dyne Therapeutics | 141 |
ARWR News
- 2 days ago - Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 10 days ago - Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases - Business Wire
- 18 days ago - Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity - Business Wire
- 19 days ago - Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences - Business Wire
- 24 days ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 25 days ago - Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results - Business Wire
- 25 days ago - Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs - Business Wire
- 4 weeks ago - Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Business Wire